iFrame is not supported! PTG-300: ASH 2022 Srdan Verstovsek Verify Phase 3 Clinical Trial By Srdan Verstovsek, MD, PhD What…
Browsing: ASH
PTG-300: ASH 2022 Srdan Verstovsek Verify Phase 3 Clinical Trial By Srdan Verstovsek, MD, PhD What were the results of…
Pembro: ASH 2022 Mwanasha Merrill Addition After Auto-SCT T-Cell NHL By Mwanasha Merrill, MD How can Pembro (MK-3475) help patients…
iFrame is not supported! Pembro: ASH 2022 Mwanasha Merrill Addition After Auto-SCT T-Cell NHL By Mwanasha Merrill, MD How can…
Pembro: ASH 2022 Mwanasha Merrill Addition After Auto-SCT T-Cell NHL By Mwanasha Merrill, MD How can Pembro (MK-3475) help patients…
MRD: ASH 2022 Gayathri Ravi Induction Quadruplet Therapy in NDMM By Gayathri Ravi, MD What can induction quadruplet therapy do…
iFrame is not supported! MRD: ASH 2022 Gayathri Ravi Induction Quadruplet Therapy in NDMM By Gayathri Ravi, MD What can…
MRD: ASH 2022 Gayathri Ravi Induction Quadruplet Therapy in NDMM By Gayathri Ravi, MD What can induction quadruplet therapy do…
GC012F: ASH 2022 Wendy Li First-Line Therapy Newly Diagnosed MM By Wendy Li, MD How can GC012F help patients with…
iFrame is not supported! GC012F: ASH 2022 Wendy Li First-Line Therapy Newly Diagnosed MM By Wendy Li, MD How can…
GC012F: ASH 2022 Wendy Li First-Line Therapy Newly Diagnosed MM By Wendy Li, MD How can GC012F help patients with…
CLL Treatments: ASH 2022 Brian Koffman Understanding Pts with CLL By Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd How…
iFrame is not supported! CLL Treatments: ASH 2022 Brian Koffman Understanding Pts with CLL By Brian Koffman, MDCM (retired), DCFP,…
CLL Treatments: ASH 2022 Brian Koffman Understanding Pts with CLL By Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd How…
Navitoclax: ASH 2022 Jalaja Potluri Disease Modification in Myelofibrosis By Jalaja Potluri, MD How can this study help modify myelofibrosis?…
iFrame is not supported! Navitoclax: ASH 2022 Jalaja Potluri Disease Modification in Myelofibrosis By Jalaja Potluri, MD How can this…
Navitoclax: ASH 2022 Jalaja Potluri Disease Modification in Myelofibrosis By Jalaja Potluri, MD How can this study help modify myelofibrosis?…
TriTAC: ASH 2022 Al-Ola Abdallah Updated Interim Results HBN217 By Al-Ola Abdallah, MD What are the updated interim results from…
iFrame is not supported! TriTAC: ASH 2022 Al-Ola Abdallah Updated Interim Results HBN217 By Al-Ola Abdallah, MD What are the…
TriTAC: ASH 2022 Al-Ola Abdallah Updated Interim Results HBN217 By Al-Ola Abdallah, MD What are the updated interim results from…
Asciminib: ASH 2022 Prof. Hughes Studies For Pts With CML By Professor Timothy Hughes, MD, MBBS, FRACP, FRCPA How can…
iFrame is not supported! Asciminib: ASH 2022 Prof. Hughes Studies For Pts With CML By Professor Timothy Hughes, MD, MBBS,…
Asciminib: ASH 2022 Prof. Hughes Studies For Pts With CML By Professor Timothy Hughes, MD, MBBS, FRACP, FRCPA How can…
Liso-cel: ASH 2022 Data From the Outreach Study By Yuliya Linhares, MD How can Liso-Cell (Lisocabtagene Maraleucel) help patients with…
iFrame is not supported! Liso-cel: ASH 2022 Data From the Outreach Study By Yuliya Linhares, MD How can Liso-Cell (Lisocabtagene…
Liso-cel: ASH 2022 Data From the Outreach Study By Yuliya Linhares, MD How can Liso-Cell (Lisocabtagene Maraleucel) help patients with…
iFrame is not supported! IPSS: ASH 2022 Roger Lyons Treatment Pattern and Overall Survival MDS By Roger M. Lyons, MD,…
iFrame is not supported! IPSS: ASH 2022 Roger Lyons Treatment Pattern and Overall Survival MDS By Roger M. Lyons, MD,…
IPSS: ASH 2022 Roger Lyons Treatment Pattern and Overall Survival MDS By Roger M. Lyons, MD, FACP What is the…
Caplacizumab: TMA Camila Masias ASH 2022 HRES Discussion By Camila Masias, MD How will Caplacizumab help patients with TMAs? I…
iFrame is not supported! Caplacizumab: TMA Camila Masias ASH 2022 HRES Discussion By Camila Masias, MD How will Caplacizumab help…
Caplacizumab: TMA Camila Masias ASH 2022 HRES Discussion By Camila Masias, MD How will Caplacizumab help patients with TMAs? I…
Polatuzumab-Rituximab: RR DLBCL Ariel Perez ASH 2022 Second-Line Therapy By Ariel Perez Perez, MD What did the combination of Polatuzumab-Rituximab…
iFrame is not supported! Polatuzumab-Rituximab: RR DLBCL Ariel Perez ASH 2022 Second-Line Therapy By Ariel Perez Perez, MD What did…
Polatuzumab-Rituximab: RR DLBCL Ariel Perez ASH 2022 Second-Line Therapy By Ariel Perez Perez, MD What did the combination of Polatuzumab-Rituximab…
Caplacizumab: TMA Camila Masias ASH 2022 Complement-Mediated HRES Debate By Camila Masias, MD How will Caplacizumab help patients with TMAs?…
iFrame is not supported! Caplacizumab: TMA Camila Masias ASH 2022 Complement-Mediated HRES Debate By Camila Masias, MD How will Caplacizumab…
Caplacizumab: TMA Camila Masias ASH 2022 Complement-Mediated HRES Debate By Camila Masias, MD How will Caplacizumab help patients with TMAs?…
iFrame is not supported! Notable Labs: Thomas Bock ASH 2022 The Future of AML Treatment By Thomas Bock, MD, MBA…
Notable Labs: Thomas Bock ASH 2022 The Future of AML Treatment By Thomas Bock, MD, MBA Where is the blood…
iFrame is not supported! VERIFY Trial PV: ASH 2022 Phase 3 Study on PTG-300 Srdan Verstovsek By Srdan Verstovsek, MD,…
VERIFY Trial PV: ASH 2022 Phase 3 Study on PTG-300 Srdan Verstovsek By Srdan Verstovsek, MD, PhD How will the…
iFrame is not supported! Idecabtagene: ASH 2022 Multiple Myeloma Madhav Dhodapkar KarMMa-2 By Madhav Dhodapkar, MBBS What is Idecabtagene, and…
Idecabtagene: ASH 2022 Multiple Myeloma Madhav Dhodapkar KarMMa-2 By Madhav Dhodapkar, MBBS What is Idecabtagene, and how can it help…
iFrame is not supported! Isatuximab: ASH 2022 Multiple Myeloma Paul Richardson ICARIA By Paul Richardson, MD What can Pomalidomide/Dexamethasone do…
Isatuximab: ASH 2022 Multiple Myeloma Paul Richardson ICARIA By Paul Richardson, MD What can Pomalidomide/Dexamethasone do for Relapsed/Refractory Multiple Myeloma…
Zanubrutinib: Superior PFS in CLL Jennifer Brown, MD – ASH 2022 By Jennifer Brown, MD I’ll be discussing the alpine…
iFrame is not supported! Pacritinib: Phase 3 PACIFICA Trial Dr. Mascarenhas ASH 2022 By John Mascarenhas, MD What is the…
Pacritinib: Phase 3 PACIFICA Trial Dr. Mascarenhas ASH 2022 By John Mascarenhas, MD What is the study of Pacritinib in…
iFrame is not supported! Dasatinib or Imatinib: Final 5-Year Results From DASCERN Dr. Cortes ASH 2022 By Jorge Cortes, MD…